untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:32:18Z</responseDate>
<request identifier=oai:HAL:inserm-00913886v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:inserm-00913886v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:SANTE_PUB_INSERM</setSpec>
<setSpec>collection:INSERM</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Primary prophylaxis of disseminated histoplasmosis in HIV patients in French Guiana: arguments for cost effectiveness.</title>
<creator>Nacher, Mathieu</creator>
<creator>Adenis, Antoine</creator>
<creator>Basurko, Celia</creator>
<creator>Vantilcke, Vincent</creator>
<creator>Blanchet, Denis</creator>
<creator>Aznar, Christine</creator>
<creator>Carme, Bernard</creator>
<creator>Couppié, Pierre</creator>
<contributor>Centre d'investigation clinique Antilles-Guyane ; Institut National de la Santé et de la Recherche Médicale (INSERM) - CH Cayenne</contributor>
<contributor>EA 3593 Université des Antilles et de la Guyane ; Centre d'investigation clinique Antilles-Guyane ; Institut National de la Santé et de la Recherche Médicale (INSERM) - CH Cayenne - Institut National de la Santé et de la Recherche Médicale (INSERM) - CH Cayenne</contributor>
<contributor>Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH Guyane) ; Centre hospitalier Andrée Rosemon (Cayenne)</contributor>
<contributor>Epidémiologie des parasitoses et mycoses tropicales ; Université des Antilles et de la Guyane (UAG) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Laboratoire Hospitalo-Universitaire de Parasitologie-Mycologie ; Centre Hospitalier de Cayenne Andrée Rosemon - Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)</contributor>
<contributor>Service de Dermatologie et Vénérologie ; Centre Hospitalier de Cayenne Andrée Rosemon</contributor>
<description>International audience</description>
<source>ISSN: 0002-9637</source>
<source>American Journal of Tropical Medicine and Hygiene</source>
<publisher>American Society of Tropical Medicine and Hygiene</publisher>
<identifier>inserm-00913886</identifier>
<identifier>http://www.hal.inserm.fr/inserm-00913886</identifier>
<identifier>http://www.hal.inserm.fr/inserm-00913886/document</identifier>
<identifier>http://www.hal.inserm.fr/inserm-00913886/file/2013_Nacher_-_Primary_prophylaxissur disseminated_histoplasmosis_in_HIV_patients_in_French_Guiana_a_cost_effectiveness_study.pdf</identifier>
<source>http://www.hal.inserm.fr/inserm-00913886</source>
<source>American Journal of Tropical Medicine and Hygiene, American Society of Tropical Medicine and Hygiene, 2013, 89 (6), pp.1195-8. 〈10.4269/ajtmh.13-0082〉</source>
<identifier>DOI : 10.4269/ajtmh.13-0082</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.4269/ajtmh.13-0082</relation>
<identifier>PUBMED : 24127168</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/24127168</relation>
<language>en</language>
<subject>[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>Histoplasmosis is the first cause of acquired immunodeficiency syndrome (AIDS) and AIDS-related deaths in French Guiana. Cohort data were used to determine whether primary prophylaxis with 100 mg itraconazole for patients with CD4 counts < 150/mm(3) was cost-effective with different scenarios. For a scenario where 12% of patients died, 60% were aware of their human immunodeficiency virus (HIV) infection and adherence was only 50%, primary prophylaxis would prevent 1 death and 9 cases of histoplasmosis for a cost of 36,792 Euros per averted death, 1,533 per life-year saved, 4,415 Euros per averted case, when only counting the costs of itraconazole prophylaxis. Taking into account the total costs of hospitalization showed that primary prophylaxis would allow a savings of 185,178 Euros per year. Even in a scenario of low adherence, primary prophylaxis would be cost-effective in French Guiana, and presumably in the rest of the Guianas and the Amazon.</description>
<date>2013-12</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
